3HR Treatment According to NTEP
The 3HR regimen (3 months of daily isoniazid and rifampicin) is recommended by NTEP for tuberculosis preventive therapy (TPT) in eligible contacts of bacteriologically confirmed TB patients, administered as daily therapy for 12 weeks.
Regimen Specifications
The 3HR regimen consists of:
- Isoniazid: 5 mg/kg (maximum 300 mg) daily
- Rifampicin: 10 mg/kg (450 mg if <50 kg; 600 mg if ≥50 kg) daily
- Duration: 3 months (12 weeks) of continuous daily therapy 1, 2
Evidence Base and Efficacy
The 3HR regimen has demonstrated strong effectiveness for latent TB infection treatment. Treatment completion rates with 3HR are superior to longer isoniazid monotherapy regimens (92.55% vs 84.97%, p=0.024), with comparable or lower hepatotoxicity rates (1.6% vs 2.37%) 3. Recent implementation data from Nigeria shows an 84.7% completion rate among 8,213 contacts enrolled on 3HR 4.
A 2025 randomized controlled trial directly comparing 4 months rifampicin (4R) versus 3HR found no significant difference in completion rates (77.9% vs 75.9%, p=0.7) or adverse event profiles, confirming 3HR as an effective shorter-course option 5.
Clinical Implementation Under NTEP
Target Population
- Close contacts of bacteriologically confirmed TB patients
- Adults and children who are TB infection-positive but disease-negative
- Particularly prioritized for household contacts and vulnerable populations including asylum seekers and migrants 4
Pre-Treatment Requirements
Before initiating 3HR, active TB disease must be excluded through:
- Clinical history and physical examination focusing on TB symptoms (cough, fever, weight loss, night sweats)
- Chest radiography
- Bacteriologic studies when indicated 6, 7
Baseline Laboratory Monitoring
Baseline hepatic function testing (AST/ALT, bilirubin) is indicated for:
- Patients with HIV infection
- Pregnant women and those within 3 months postpartum
- History of chronic liver disease (hepatitis B/C, alcoholic hepatitis, cirrhosis)
- Regular alcohol users
- Persons taking other hepatotoxic medications 6, 7
Routine baseline testing is not required for otherwise healthy individuals without risk factors.
Follow-Up Schedule
Patients on 3HR should receive:
- Follow-up evaluations at 2,4, and 8 weeks (more frequent than isoniazid monotherapy)
- Assessment for side effects at each visit
- Brief physical examination checking for signs of hepatitis
- Patient education about stopping treatment immediately if symptoms develop (jaundice, dark urine, nausea, vomiting, abdominal pain, unexplained fatigue) 6, 7
Special Populations
HIV-Positive Patients
The 3HR regimen is effective in HIV-infected persons, though drug-drug interactions with antiretroviral therapy must be carefully evaluated, particularly with protease inhibitors and rifampicin. Rifabutin may be substituted when rifampicin cannot be used 6, 7.
Pregnant Women
While rifampicin is generally safe in pregnancy, pyrazinamide is not routinely recommended due to inadequate teratogenicity data. The 3HR regimen (without pyrazinamide) can be used, though some experts recommend delaying treatment until after delivery for women at lower risk 7, 2.
Children
The 3HR regimen is appropriate for pediatric contacts, with weight-based dosing:
- Isoniazid: 10-20 mg/kg (maximum 300 mg) daily
- Rifampicin: 10 mg/kg (maximum 600 mg) daily 8
Common Pitfalls and Caveats
Drug Resistance Considerations
3HR should NOT be used for contacts of isoniazid-resistant TB cases. For isoniazid-resistant, rifampicin-susceptible source cases, alternative regimens (rifampicin alone for 4 months or rifampicin-pyrazinamide for 2 months) should be considered 6, 7.
Adherence Strategies
Given that non-adherence is the primary cause of treatment failure, directly observed therapy (DOT) is strongly recommended, especially for:
- Patients with history of non-adherence
- Injection drug users
- Persons experiencing homelessness
- Alcoholics 9
Facilitators of completion include healthcare worker training, thorough counseling sessions, and addressing misconceptions about side effects. Barriers include medication stockouts and inadequate follow-up strategies 4.
Hepatotoxicity Management
If AST/ALT rises to 5 times normal or bilirubin rises, all hepatotoxic drugs should be stopped immediately. Once liver function normalizes, drugs can be reintroduced sequentially (isoniazid first, then rifampicin) with close monitoring 8.
Monitoring Compliance
Rifampicin causes orange/pink discoloration of urine, which can be used as a simple visual check for adherence. More formal methods include urine testing for isoniazid metabolites 2.
Comparison with Alternative Regimens
While 3HR offers excellent completion rates and tolerability, other WHO-recommended options include:
- 6-9 months isoniazid monotherapy (lower completion, more hepatotoxicity)
- 4 months rifampicin monotherapy (similar efficacy and completion to 3HR)
- 3 months weekly rifapentine plus isoniazid (requires DOT, not widely available in India)
The 3HR regimen represents an optimal balance between treatment duration, efficacy, safety, and completion rates for NTEP's TB preventive therapy program 10, 11, 5.